Literature DB >> 2729953

Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

I Shalit1, S A Berger, A Gorea, H Frimerman.   

Abstract

Ofloxacin and ciprofloxacin resistance (MIC, greater than 4 micrograms/ml) was encountered in 45 of 50 clinical isolates of methicillin-resistant Staphylococcus aureus. None of 20 methicillin-susceptible strains was resistant to the quinolones (P less than 10(-6). Quinolone-susceptible and -resistant isolates did not differ with respect to culture source or bacteriophage type. The future usefulness of quinolones for S. aureus infection may be limited.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2729953      PMCID： PMC172489          DOI： 10.1128/AAC.33.4.593

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance.

Authors:  V E Del Bene; J F John; J A Twitty; J W Lewis
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

2.  In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.

Authors:  R N Greenberg; D J Kennedy; P M Reilly; K L Luppen; W J Weinandt; M R Bollinger; F Aguirre; F Kodesch; A M Saeed
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.

Authors:  L J Chalkley; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.

Authors:  K E Aldridge; A Janney; C V Sanders
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

8.  In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

9.  Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  M Gilbert; J A Boscia; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

10.  Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.

Authors:  J K Foster; J R Lentino; R Strodtman; C DiVincenzo
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191
  10 in total
  69 in total

1.  Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

2.  In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985.

Authors:  P Van der Auwera; C Godard; C Denis; S De Maeyer; R Vanhoof
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990.

Authors:  A L Barry; P C Fuchs; M A Pfaller; S D Allen; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

4.  Synergism of trimethoprim and ciprofloxacin in vitro against clinical bacterial isolates.

Authors:  P Huovinen; J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

5.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

6.  Activity of new quinolones against ciprofloxacin-resistant staphylococci.

Authors:  G J Forstall; C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 7.  The epidemiology of bacterial resistance to quinolones.

Authors:  J F Acar; T F O'Brien; F W Goldstein; R N Jones
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

9.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Biological characterization of cyclothialidine, a new DNA gyrase inhibitor.

Authors:  N Nakada; H Shimada; T Hirata; Y Aoki; T Kamiyama; J Watanabe; M Arisawa
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.